康柏西普玻璃体内注射联合视网膜激光光凝术治疗糖尿病性黄斑水肿的疗效观察  

Observation on Curative Effect of Intravitreal Injection of Conbercept combined with Retinal Laser Photocoagulation in the Treatment of Diabetic Macular Edema

作　　者：李维欣[1] 谢桂丽 孙晓敏[1] 王宇鹰[1] LI Wei-xin;XIE Gui-li;SUN Xiao-min;WANG Yu-ying(Department of Ophthalmology II,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Ophthalmology I,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州大学第一附属医院眼科二病区,郑州450000 [2]郑州大学第一附属医院眼科一病区,郑州450000

出　　处：《中国合理用药探索》2022年第1期96-101,共6页Chinese Journal of Rational Drug Use

基　　金：河南省高等学校重点科研项目计划(19B320031)。

摘　　要：目的:探讨康柏西普玻璃体内注射联合视网膜激光光凝术治疗糖尿病性黄斑水肿(DME)的疗效。方法:选取2017年6月~2020年6月本院收治的500例DME患者作为研究对象,按照随机数字表法分为对照组和观察组,各250例。对照组采取视网膜激光光凝术治疗,观察组在对照组基础上联合康柏西普玻璃体内注射治疗。比较两组治疗前、治疗1个月、治疗3个月的最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT),以及细胞因子[血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)、可溶性细胞间黏附分子-1(sICAM-1)]水平;记录两组不良反应发生情况。结果:治疗1个月和3个月,观察组BCVA高于对照组(P<0.05),CMT及VEGF、IL-6、sICAM-1水平低于对照组(P<0.05)。治疗期间,两组不良反应总发生率比较无统计学差异(P>0.05)。结论:康柏西普玻璃体内注射联合视网膜激光光凝术能提高DME患者视力,降低视网膜厚度,疗效较好,且安全性较高。Objective:To explore the curative effect of intravitreal injection of conbercept combined with retinal laser photocoagulation in the treatment of diabetic macular edema(DME).Methods:500 patients with DME treated in our hospital from June 2017 to June 2020 were selected as the research subjects.According to random number table method,they were divided into control group and observation group,with 250 cases in each group.The control group was treated with retinal laser photocoagulation,and the observation group was treated with conbercept intravitreal injection on the basis of the control group.Best corrected visual acuity(BCVA),central macular thickness(CMT),and levels of cytokines[vascular endothelial growth factor(VEGF),interleukin-6(IL-6)and soluble intercellular adhesion molecule-1(sICAM-1)]of the two groups were compared before treatment,1 month after treatment and 3 months after treatment.The adverse reactions of the two groups were recorded.Results:At 1 month after treatment and 3 months after treatment,BCVA of the observation group was higher than that of the control group(P<0.05),and CMT,VEGF,IL-6 and sICAM-1 were lower than those of the control group(P<0.05).During the treatment period,there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Intravitreal injection of conbercept combined with retinal laser photocoagulation can improve visual acuity and reduce retinal thickness of patients with DME.It has good curative effect and high safety.

关 键 词：康柏西普 视网膜激光光凝术 糖尿病性黄斑水肿 血管内皮生长因子 不良反应 

分 类 号：R988.1[医药卫生—药品]